The main therapeutic areas are cancer, glaucoma, obesity, and other. Research is primarily target-oriented with opportunities in various therapies. The group has designed and patented compounds that inhibit human heat shock protein 90 (Hsp90) and shown compound efficacy in xenograft mice. We have also designed and patented compounds that specifically inhibit several cancer-oriented carbonic anhydrases (CAs), especially CA IX. The group has also made anti-CA IX monoclonal antibodies and various other recombinant proteins, mostly epigenetically gene-modifying enzymes, histone deacetylases, sirtuins, methyl transferases and other.